GAJOFATTO, Alberto
 Distribuzione geografica
Continente #
NA - Nord America 4.084
EU - Europa 3.777
AS - Asia 1.319
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 7
SA - Sud America 4
Totale 9.212
Nazione #
US - Stati Uniti d'America 4.066
CN - Cina 1.140
GB - Regno Unito 1.111
IT - Italia 913
SE - Svezia 423
FR - Francia 344
IE - Irlanda 314
DE - Germania 216
FI - Finlandia 195
BE - Belgio 86
VN - Vietnam 67
UA - Ucraina 56
RU - Federazione Russa 42
IR - Iran 25
IN - India 19
CA - Canada 15
CH - Svizzera 14
KR - Corea 14
JP - Giappone 13
HK - Hong Kong 11
MK - Macedonia 11
TR - Turchia 10
GR - Grecia 8
NL - Olanda 8
ES - Italia 7
EU - Europa 7
IL - Israele 7
AU - Australia 6
NO - Norvegia 5
SD - Sudan 5
DK - Danimarca 4
EG - Egitto 4
AT - Austria 3
CL - Cile 3
CY - Cipro 3
PL - Polonia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
JO - Giordania 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LV - Lettonia 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
BD - Bangladesh 1
BR - Brasile 1
CR - Costa Rica 1
HU - Ungheria 1
IM - Isola di Man 1
LU - Lussemburgo 1
MO - Macao, regione amministrativa speciale della Cina 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
RO - Romania 1
SA - Arabia Saudita 1
SC - Seychelles 1
SI - Slovenia 1
TH - Thailandia 1
Totale 9.212
Città #
Southend 987
Chandler 786
Ashburn 408
Woodbridge 382
Ann Arbor 374
Jacksonville 331
Dublin 314
Beijing 227
Verona 172
Houston 147
New York 138
Wilmington 126
Lawrence 122
Princeton 122
Jinan 107
Nanjing 99
Hebei 88
Brussels 86
Shenyang 85
Helsinki 68
Milan 60
Washington 54
Tianjin 44
Dong Ket 43
Lancaster 43
Redwood City 42
Zhengzhou 41
Ningbo 40
Changsha 38
Haikou 37
Nanchang 37
Hangzhou 35
Redmond 35
Taiyuan 29
Sindelfingen 28
Taizhou 27
Rome 24
Seattle 23
Fuzhou 21
Guangzhou 21
Dearborn 20
Falls Church 20
Tehran 20
Jiaxing 19
Norwalk 18
Padova 18
Bologna 16
Los Angeles 15
Catania 14
Hanover 14
Clearwater 13
Lanzhou 13
Boardman 12
Düsseldorf 11
Seongbuk-gu 11
Skopje 11
Auburn Hills 10
Riva 10
Tappahannock 10
Fairfield 9
Florence 9
Kemerovo 9
Dongguan 8
Bisenti 7
Bolzano 7
Bronte 7
Loreggia 7
Tokyo 7
Arco 6
Bari 6
Boydton 6
Hong Kong 6
Sassari 6
Brescia 5
Cagliari 5
Catanzaro 5
Chicago 5
Chions 5
Dallas 5
Genoa 5
Genova 5
Lugano 5
Naples 5
Orzivecchi 5
Paris 5
Seriate 5
Trento 5
Buffalo 4
Fairport 4
London 4
Louisville 4
Novokuznetsk 4
Phoenix 4
San Diego 4
Segrate 4
Shanghai 4
Villafranca di Verona 4
Yonkers 4
Ardabil 3
Asyut 3
Totale 6.386
Nome #
Psicologia positiva e disabilità: affrontare le sfide del futuro nell'adulto con disabilità acquisita, cronica e progressiva 339
Gestione degli eventi avversi dei farmaci modificanti il decorso della malattia nella sclerosi multipla 181
Tolebrutinib. Bruton tyrosine kinase (BTK) inhibitor Treatment of multiple sclerosis 180
Un caso di sclerosi multipla con esordio "tumor-like" e decorso benigno 168
Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study 134
Two sisters with Leukoencephalopathy, hearing loss and retinopathy: a familial case of Susac's Syndrome? 122
A randomized controlled trial of IV immunoglobulin in patients with postpolio syndrome. 121
Prevalence of multiple sclerosis in Verona, Italy: an epidemiologic and genetic study 116
Clinical and biomarker assessment of demyelinating events suggesting multiple sclerosis. 113
Levofloxacin-induced hemichorea-hemiballism in a patient with previous thalamic infarction 110
QTc interval in patients with multiple sclerosis: an inference from the insula of Reil? 109
A Case-control study of myelin oligodendrocyte glycoprotein and CD45 polymorphisms in multiple sclerosis in Verona, Italy 106
A case of multifocal CIS with unusual MRI features suggestive of Balo's concentric sclerosis 103
Cognitive onset in multiple sclerosis 102
Risk factors for post-polio syndrome among an Italian population: a case-control study. 101
Intravenous immunoglobulin for post-polio syndrome: a randomized double-blind, placebo-controlled study 101
Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder 101
Analisi delle alterazioni funzionali dell’arto superiore e dell’attività muscolare mediante emgs in pazienti con sclerosi multipla: uno studio “cross-sectional” 99
Sensory integration balance training in patients with multiple sclerosis: A randomized, controlled trial 97
Biopsychosocial model of resilience in young adults with multiple sclerosis (BPS-ARMS): an observational study protocol exploring psychological reactions early after diagnosis 97
Can the degree of meningeal inflammation and cortical pathology be used to stratify early progressive MS patients? 96
Prevalence of multiple sclerosis in Verona, Italy: an epidemiological and genetic study. 95
Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients? 93
An active case of radiologically isolated syndrome: from MRI detection to multiple sclerosis 93
EFFETTI DI UN TRAINING DI INTEGRAZIONE SENSORI – MOTORIA SUI DISTURBI DELL’EQUILIBRIO IN PAZIENTI CON SCLEROSI MULTIPLA: UNO STUDIO RANDOMIZZATO CONTROLLATO 93
Clinical and demographic predictors of response to first-line therapies in relapsing-remitting multiple sclerosis 91
Regional distribution and evolution of grey matter changes in different MS phenotypes: a 5-year longitudinal study 91
The diagnosis of multiple sclerosis: pinpointing the concept of "no better explanation" 90
A case of acute fulminant multiple sclerosis treated with alemtuzumab 90
Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders 88
Regional distribution and evolution of gray matter damage in different populations of multiple sclerosis patients 87
High-intensity robot-assisted hand training in individuals with multiple sclerosis: a randomized, controlled, single-blinded trial 87
HCV-related nervous system disorders. 86
An exploratory panel of cerebrospinal fluid biomarkers compared to standard diagnostic evaluation in initial demyelinating events suggestive of multiple sclerosis 85
Benign multiple sclerosis: physical and cognitive impairment follow distinct evolutions 84
GLI EFFETTI DI DUE DIVERSI TIPI DI TRATTAMENTO MOTORIO SULLE FUNZIONI COGNITIVE IN PAZIENTI CON SCLEROSI MULTIPLA 84
A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band 84
Response to Nagai et al. 84
Physical disability and cognitive impairment evolution in benign multiple sclerosis: a five years prospective study 82
Late-onset multiple sclerosis presenting with cognitive dysfunction and severe cortical/infratentorial atrophy. 81
Brentuximab vedotin: axonal microtubule's Apollyon 81
A panel of exploratory CSF biomarkers in patients with an initial demyelinating event of the CNS: does it add relevant information to usual work-up? 80
Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study 79
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis 79
Assessment of outcome predictors in first-episode acute myelitis: a retrospective study of 53 cases. 78
Two sisters with leukoencephalopathy, hearing loss and retinopathy: a familial case of Susac's syndrome? 76
Long-term clinical, cognitive and MRI characteristics of patients with untreated benign multiple sclerosis: a natural history study 76
Correlation between cerebrospinal fluid markers of neurodegeneration and MRI measures of gray matter pathology in multiple sclerosis 76
EFFECTIVENESS OF A SENSORIMOTOR INTEGRATION TRAINING ON BALANCE DISORDERS IN PATIENTS WITH MULTIPLE SCLEROSIS: A RANDOMIZED CONTROLLED TRIAL 76
A case of multiple sclerosis and necrotizing autoimmune myopathy with anti-SRP antibodies 76
Epilepsy in multiple sclerosis: The role of temporal lobe damage 76
Long lesions on initial spinal cord MRI predict a final diagnosis of acute disseminated encephalomyelitis versus multiple sclerosis in children 75
Physicochemical properties of Aβ peptides in cerebrospinal fluid of Alzheimer’s disease patients 75
Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015 75
Long survival and clinical stability in Marburg's variant multiple sclerosis. 74
Increased cortical lesion load and CSF cytokines in oligoclonal band positive MS patients 74
Effects of high-intensity robot-assisted training in hand function recovery and adl independence in individuals with multiple sclerosis: A randomized controlled single-blinded trial 73
Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis 73
Prognostic value of multimodal evoked potentials in multiple sclerosis: the EP score. 72
Prognostic factors of acute partial transverse myelitis. 72
Early predictors of recovery, symptom recurrence, conversion to multiple sclerosis and long-term disability after acute myelitis 72
Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis 72
"If you can't control the wind, adjust your sail": tips for post-pandemic benefit finding from young adults living with multiple sclerosis. A qualitative study 72
Acute cardiovascular dysfunction in multiple sclerosis: report of two cases and literature review 71
Cerebrospinal fluid markers in sporadic Creutzfeldt-Jakob disease. 70
Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study 70
HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod 70
Benign course of tumour-like multiple sclerosis. Report of five cases and literature review. 69
Clinical, MRI, and CSF markers of disability progression in multiple sclerosis 69
Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study. 68
A bio-psycho-social co-created intervention for young adults with multiple sclerosis (ESPRIMO): rationale and study protocol for a feasibility study 68
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study) 67
2017 McDonald criteria for multiple sclerosis: Earlier diagnosis with reduced specificity? 67
Prognostic indicators of “benign” clinical course in multiple sclerosis patients. 66
Increased cerebrospinal fluid cystatin C may predict disability after acute myelitis 66
Mycobacterium avium subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by sera from patients with Neuromyelitis optica spectrum disorder 66
Amyloid myopathy: an intriguing diagnosis 65
Insights for fostering resilience in young adults with multiple sclerosis in the aftermath of the COVID-19 emergency: an Italian survey 65
Characterization of Upper Limb Impairments at Body Function, Activity, and Participation in Persons With Multiple Sclerosis by Behavioral and EMG Assessment: A Cross-Sectional Study 64
Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases 63
Assessing subjective quality of life domains after multiple sclerosis diagnosis disclosure 62
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 62
Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. 61
Inflammatory intrathecal profiles and cortical damage in multiple sclerosis 61
"Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study 60
Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status 59
Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: an Italian multi-centre study 59
Up-regulated serum miR-128-3p in progressive and relapse-free multiple sclerosis patients 59
Tumor-like multiple sclerosis: three cases misdiagnosed as primary brain neoplasm 58
Effects of high-intensity robot-assisted hand training on upper limb recovery and muscle activity in individuals with multiple sclerosis: a randomized, controlled, single-blinded trial 58
Diagnostic features of initial demyelinating events associated with serum MOG-IgG 58
Increase of CSF inflammatory profile in a case of highly active multiple sclerosis 58
Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy. 57
Impact of switching first-line disease-modifying therapy after treatment failure in relapsing-remitting multiple sclerosis 57
Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives 55
Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? 53
Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date 53
Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD 52
Evaluating upper upper limb dysfunctions in patients with multiple sclerosis: an electromyography cross sectional study 51
Investigational immunosuppressants in early stage clinical trials for the treatment of multiple sclerosis 49
Totale 8.382
Categoria #
all - tutte 26.385
article - articoli 24.775
book - libri 0
conference - conferenze 739
curatela - curatele 0
other - altro 203
patent - brevetti 0
selected - selezionate 0
volume - volumi 668
Totale 52.770


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201976 0 0 0 0 0 0 0 0 10 25 17 24
2019/20201.005 115 22 19 55 180 72 153 30 52 114 91 102
2020/20211.169 142 223 79 116 137 103 28 41 65 35 104 96
2021/20221.177 98 418 31 123 27 23 11 74 36 32 74 230
2022/20232.315 153 291 212 372 175 483 39 146 256 41 91 56
2023/20241.484 72 117 193 168 271 402 92 154 15 0 0 0
Totale 9.419